Basilea Pharmaceutica AG (BSLN.S)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|53||2016||Chairman of the Board of Directors|
|51||2018||Chief Executive Officer, Member of the Management Committee|
|2019||Chief Financial Officer|
|2018||Chief Technology Officer|
|2009||Member of the Management Committee, Chief Scientific Officer|
- Swiss stocks - Factors to watch on July 1
- BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer
- Swiss stocks - Factors to watch on June 3
- BRIEF-Basilea Pharmaceutica Publishes Clinical Data For Anticancer Drug Candidates BAL101553
- Swiss stocks - Factors to watch on May 2